

Criteria Grid
Best Practices and Interventions for the Diagnosis and Treatment of Hepatitis C

| | | | | |
|--|--|--------------------------|--------------------------|--------------------------------------|
| Best Practice/Intervention: | McHutchison et al. (2009b), Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection, <i>N Eng J Med</i> 360(18), 1827-1838. | | | |
| Date of Review: | March 17, 2011 | | | |
| Reviewer(s): | Alison Marshall | | | |
| Part A | | | | |
| Category: | Basic Science <input type="checkbox"/> Clinical Science <input checked="" type="checkbox"/> Public Health/Epidemiology <input type="checkbox"/> Social Science <input type="checkbox"/> Programmatic Review <input type="checkbox"/> | | | |
| Best Practice/Intervention: | Focus: Hepatitis C <input checked="" type="checkbox"/> Hepatitis C/HIV <input type="checkbox"/> Other: _____ Level: Group <input checked="" type="checkbox"/> Individual <input type="checkbox"/> Other: _____ Target Population: <u>Persons infected with genotype 1 HCV infection, adults 18-65 years</u> Setting: Health care setting/Clinic <input checked="" type="checkbox"/> Home <input type="checkbox"/> Other: _____ Country of Origin: <u>USA</u> Language: English <input checked="" type="checkbox"/> French <input type="checkbox"/> Other: _____ | | | |
| Part B | | | | |
| | YES | NO | N/A | COMMENTS |
| <i>Is the best practice/intervention a meta-analysis or primary research?</i> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Primary Research |
| <i>The best practice/intervention has utilized an evidence-based approach to assess:</i> | | | | |
| <i>Efficacy</i> | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | |
| <i>Effectiveness</i> | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | |
| <i>The best practice/intervention has been evaluated in more than one patient setting to assess:</i> | | | | |
| <i>Efficacy</i> | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | 3 treatment groups + 1 control group |
| <i>Effectiveness</i> | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | |

| | YES | NO | N/A | COMMENTS |
|---|-------------------------------------|-------------------------------------|--------------------------|--|
| <i>The best practice/intervention has been operationalized at a multi-country level:</i> | | | | |
| <i>There is evidence of capacity building to engage individuals to accept treatment/diagnosis</i> | <input type="checkbox"/> | <input checked="" type="checkbox"/> | <input type="checkbox"/> | |
| <i>There is evidence of outreach models and case studies to improve access and availability</i> | <input type="checkbox"/> | <input checked="" type="checkbox"/> | <input type="checkbox"/> | |
| <i>Do the methodology/results described allow the reviewer(s) to assess the generalizability of the results?</i> | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Methodology/results generalizable across developed countries. |
| <i>Are the best practices/methodology/results described applicable in developed countries?</i> | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Took place across 37 centres in the USA. |
| <i>Are the best practices/methodology/results described applicable in developing countries?</i> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Access to medicines and length of treatment uptake presents difficulties. |
| <i>Evidence of manpower requirements is indicated in the best practice/intervention</i> | <input type="checkbox"/> | <input checked="" type="checkbox"/> | <input type="checkbox"/> | |
| <i>Juried journal reports of this treatment, intervention, or diagnostic test have occurred</i> | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Comments in <i>N Engl J Med</i> and <i>J Hepatol</i> |
| <i>International guideline or protocol has been established</i> | <input type="checkbox"/> | <input checked="" type="checkbox"/> | <input type="checkbox"/> | |
| <i>The best practice/intervention is easily accessed/available electronically</i> | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Available electronically in the <i>New England Journal of Medicine</i> . |
| <i>Is there evidence of a cost effective analysis? If so, what does the evidence say?</i> Please go to Comments section | <input type="checkbox"/> | <input checked="" type="checkbox"/> | <input type="checkbox"/> | |
| <i>How is the best practice/intervention funded?</i> Please go to Comments section | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Vertex Pharmaceuticals. |
| <i>Other relevant criteria:</i> Notable Findings <hr/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <ul style="list-style-type: none"> • Treatment with telaprevir significantly improved sustained virologic response rates; • Sustained virologic response from black participants, although lower than white participants, was a promising 44%; • Participants in the telaprevir group had higher rates of discontinuation |

| | | | | |
|--|--|--|--|---|
| | | | | because of adverse effects (most commonly, rashes). |
|--|--|--|--|---|